Lilly expands manufacturer distribution for Zepbound amid compounding safety concerns and pricing pushback
Key Questions
What are the key clinical results for Zepbound from the SURMOUNT-5 trial?
Zepbound topped the Pharma50 rankings via the SURMOUNT-5 trial, achieving 20.2% weight loss. This positions it as a leading option in the GLP-1 market.
How does Zepbound compare to Wegovy in sales and market share?
Zepbound generated $13.5B in sales, surpassing Wegovy, and holds a 60% market share. This reflects strong demand amid expanding distribution.
What are the current pricing options for Zepbound?
Self-pay pricing is $299 per month, while Kroger and Employer Connect options are $449 per month. These rates come amid pricing pushback and manufacturer distribution expansion.
Pharma50 top via SURMOUNT-5 20.2% WL; Zepbound $13.5B > Wegovy; 60% share; self-pay $299/mo, Kroger/Employer Connect $449/mo; UK threat Sept 1; BALANCE May 2026; Ricks resists permanent Trump pricing deals; Medicare $50 cap. Hims/Novo deal squeezes telehealth, accelerates branded shift + orforglipron.